Condition: Breast Cancer · Breast Neoplasms · Breast Neoplasm Female · Sponsor: Institut fuer Frauengesundheit
This is a single-arm, open-label phase IV study of patients with advanced HR+/HER2- breast cancer who are treated first line with ribociclib and standard of care endocrine treatment according to SmPC.
This description comes directly from the study's public registry record.
CAPTOR Study Manager · 09131 9278638 · captor@ifg-erlangen.de
Always discuss trial participation with your own doctor first.
| Department of Gynecology and Obstetrics, Erlangen University Hospital | Erlangen, Bavaria, Germany | Recruiting |
| Department of Gynecology and Obstetrics, University Medicine Mainz | Mainz, Hesse, Germany | Recruiting |
| Department for Gynecology and Obstetrics, Marienhospital Bottrop gGmbH | Bottrop, North Rhine-Westphalia, Germany | Recruiting |
| Klinikum St Marien Amberg | Amberg, Germany | Recruiting |
| Onkologie Aschaffenburg, Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg | Aschaffenburg, Germany | Recruiting |
| Klinik für Hämatologie und Onkologie, Uniklinik Augsburg | Augsburg, Germany | Not Yet Recruiting |
| University Hospital Augsburg | Augsburg, Germany | Recruiting |
| Frauenklinik des Klinikums Bamberg | Bamberg, Germany | Not Yet Recruiting |
| MediOnko GbR | Berlin, Germany | Not Yet Recruiting |
| HELIOS Klinikum Berlin-Buch | Berlin, Germany | Not Yet Recruiting |
| Zentrum für ambulante Hämatologie und Onkologie (ZAHO) an der Robert-Janker-Klinik | Bonn, Germany | Not Yet Recruiting |
| Klinik für Gynäkologie, Gynäkoonkologie und Senologie Klinikum Bremen-Mitte | Bremen, Germany | Not Yet Recruiting |
+ 40 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05452213